Literature DB >> 18985342

Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction.

Hinrich Wieder, Wolfgang Weber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18985342     DOI： 10.1007/s00259-008-0973-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  7 in total

1.  Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09       Impact factor: 9.236

2.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

3.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Authors:  Katja Ott; Wolfgang A Weber; Florian Lordick; Karen Becker; Raymonde Busch; Ken Herrmann; Hinrich Wieder; Ulrich Fink; Markus Schwaiger; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

4.  Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.

Authors:  Hinrich A Wieder; Katja Ott; Florian Lordick; Karen Becker; Alexander Stahl; Ken Herrmann; Ulrich Fink; Jörg Rüdiger Siewert; Markus Schwaiger; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-07       Impact factor: 9.236

5.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

6.  Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.

Authors:  B M Smithers; G C Couper; J M Thomas; D Wong; D C Gotley; I Martin; J A Harvey; D B Thomson; E T Walpole; N Watts; B H Burmeister
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

7.  (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.

Authors:  C M Gillham; J A Lucey; M Keogan; G J Duffy; V Malik; A A Raouf; K O'byrne; D Hollywood; C Muldoon; J V Reynolds
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
  7 in total
  1 in total

1.  Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.

Authors:  R C Fields; V E Strong; M Gönen; K A Goodman; N P Rizk; D P Kelsen; D H Ilson; L H Tang; M F Brennan; D G Coit; M A Shah
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.